ライフサイエンスコーパス: a panel of

1 A panel of 10 diabetes and obesity serum markers was det

2 A panel of 10 expert spine surgeons was formed to review

3 orated with partner organizations to convene a panel of 10 experts on healthcare-associated ventricul

4 sed on the relative abundance, we identified a panel of 11 proteins to distinguish CRC from AT.

5 To do so, we measured a panel of 12 inflammatory, angiogenic, and oxidative st

6 fluorescent protein (EGFP) reporter gene in a panel of 12 organs after IP injection.

7 an lymphoblastoid cell lines, was applied to a panel of 12 patient-derived xenograft (PDX) models of

8 In this study we have compared expression of a panel of 13 reported anti-HIV miRNAs in human PBMCs fr

9 an unbiased systems-approach to interrogate a panel of 14 well-annotated HGS-OvCa patient-derived xe

10 A panel of 140 clinical fungal isolates was used in both

11 Individual QMs within a panel of 15 QMs previously developed to assess the qua

12 Angeles (UCLA) Appropriateness Methodology, a panel of 16 patients, family members, injury and quali

13 We have analyzed a panel of 17 KRAS mutant lung cancer cell lines classif

14 correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines.

15 Here we report the synthesis of a panel of 2-aryl-5-carboxytetrazole-lysine analogs (ACT

16 ally identical to that of 10E8, a potency on a panel of 200 HIV-1 isolates also similar to that of 10

17 (CPROBE) cohort of 1235 adults, we selected a panel of 214 36 with stage 1 or 2 CKD, 99 with stage 3

18 in-like growth factor 1 receptor (IGF-1R) in a panel of 22 protein kinases and in cells.

19 Among 254 metabolites identified, a panel of 25 metabolites showed high sensitivity (84%)

20 Therefore, we developed and exploited a panel of 26 yeast-based functional complementation ass

21 e used as features to predict sensitivity to a panel of 27 drugs.

22 Utilizing a panel of 28 distinct human, avian, and swine influenza

23 enes belonging to the coagulation cascade in a panel of 29 BMs and we identified 56 Single Nucleotide

24 A panel of 30 maize lines was evaluated with and without

25 ring a 1-h EGF stimulation time course using a panel of 35 antibodies.

26 s correlated to MYC/MYCN/MYCL1 expression in a panel of 35 cancer cell lines.

27 We developed a panel of 35 ECM, ECM-related, and lung-specific analyt

28 We sequenced whole genomes or a panel of 365 genes on 299 samples from 170 patients wi

29 13 traits were identified using eRD-GWAS on a panel of 369 maize inbred lines.

30 receptors and used this difference to screen a panel of 37 Agam/Or15 mutants, surveying all positions

31 d non-small cell lung cancer line (H3122) to a panel of 4 ALK TKIs, and performed a collateral sensit

32 protein (MBP; MBP-CAP-1 to 4) and binding to a panel of 4 recombinant allergens were compared in CCD-

33 Studies in a panel of 40 HCC cell lines and 30 HCC PDX models showe

34 We screened a panel of 41 bacterial strains as a platform to determi

35 itative proteome analysis' (IMAHP) method to a panel of 41 breast cancer cell lines and show that dev

36 excellent selectivity in a screening against a panel of 410 kinases.

37 and performed error-corrected sequencing on a panel of 46 genes on 80 patients with congenital neutr

38 variety of hematologic malignancies against a panel of 48 drug combinations.

39 We screened a panel of 49 established human head and neck squamous c

40 We extracted a panel of 5' and 3' untranslated regions that control p

41 We employed our approach to capture a panel of 5000 STRs from a test group of diademed sifak

42 vivo substrates, we analyzed the cleavage of a panel of 51 active recombinant cytokines and chemokine

43 A panel of 57 organisms corresponding to 10 different sp

44 From this, we identified a panel of 6 genes, ALDH1A1, HSP90AB1, KIT, KRT16, SPRR3

45 factor (HES1) in colon tissues from mice and a panel of 60 human colorectal cancer specimens (27 left

46 0 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines

47 In accuracy studies performed using a panel of 80 curated clinical isolates, rates of essent

48 ere we used natural genetic variation across a panel of 81 Drosophila lines to measure changes in tra

49 A panel of 9 cytokines, measured in serum before treatme

50 ss-reactivity was seen during the testing of a panel of 95 specimens with potentially interfering sub

51 and is selective for the JAK family against a panel of 97 kinases.

52 The in vitro temporal response profiles of a panel of A2A agonists were studied using cAMP assays i

53 We then characterized a panel of ABT-199-resistant myeloid leukemia cell lines

54 cation was assessed by de novo genotyping in a panel of additional 117 cases and 380 controls, and in

55 Here, a panel of affinity-variant CARs were constructed target

56 haracterize DC-SIGN-binding glycoproteins in a panel of allergenic and non-allergenic foods.

57 rize this non-canonical function, we created a panel of ALT cells with recombinant expression of TERT

58 Using a panel of AMD biomarkers and candidate drug screening,

59 phosphorylation, and induced cytotoxicity in a panel of AML cell lines.

60 modulate the TLR4 signaling, we present here a panel of amphiphilic guanidinocalixarenes whose struct

61 to form distinct conformations recognized by a panel of amyloid conformation-specific monoclonal anti

62 y the pharmacokinetics and tumor delivery of a panel of anti-EphA2 monoclonal antibodies (mAbs) with

63 Comparison of a panel of anti-lipid A antibodies reveals highly specif

64 mAb, the corresponding allergen Bet v 1, and a panel of antibodies specific for peptides spanning the

65 ur new nanotechnology, "flow virometry", and a panel of antibodies that discriminate between various

66 HA-pretreated dormant rings (DP-rings) using a panel of antimalarial drugs, including the Plasmodium

67 Here we screened a panel of antivirals for parasite and LRV1 inhibition,

68 e Demographic and Health Surveys to assemble a panel of approximately 300,000 live births in 20 count

69 of a gold nanoparticle (AuNP) complexed with a panel of aptamers.

70 The activities of a panel of b12 monoclonal Fc variants further identified

71 t here that NOTCH3 signals constitutively in a panel of basal breast cancer cell lines and in more th

72 We measured a panel of biomarkers representing four pathophysiologic

73 To characterize the temporal pattern of a panel of blood and urinary biomarkers in an animal mod

74 We examined a panel of bNAbs for their ability to neutralize HIV-1 T

75 nder (T/F) clones for their sensitivities to a panel of bNAbs in cell-free and cell-to-cell infection

76 ased reporter assay, we screened C4a against a panel of both known and orphan G protein-coupled recep

77 53beta is critical to define invasiveness in a panel of breast and colon cell lines, expressing WT or

78 Here, we investigated the sensitivity of a panel of breast cancer cell lines to treatment with va

79 A panel of breast cancer cell lines was treated with inc

80 , greatly enhanced Dox treatment efficacy in a panel of breast cancer cell lines.

81 acids to identify possible addictions across a panel of breast cancer cells.

82 In this study, a panel of broadly neutralizing antibodies (bnAbs) and n

83 in comparison with natural immunity, we used a panel of broadly neutralizing antibodies to identify t

84 ein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR inhib

85 antiproliferative activity in vitro against a panel of cancer cell lines and, for selected highly ac

86 Evaluation of 13-d in a panel of cancer cell lines showed a selective inhibiti

87 n T-cell leukemia Jurkat cells compared with a panel of cancer cell lines via inducing caspase-depend

88 In a panel of cancer cell lines, ATRi selectively induced r

89 ncing-based screening of an shRNA library on a panel of cancer cells of different origins as well as

90 miR-221 and upregulation of p27 and PUMA in a panel of cancer cells, culminating in cell death.

91 Finally, tested in a panel of cancer cells, the water-soluble form of 3a, c

92 7 transcription but not its protein level in a panel of cancer cells.

93 nd proliferation, and were more sensitive to a panel of cancer drugs compared with GC of a more diffe

94 otent target antigen-restricted apoptosis in a panel of cancer lines and in primary patient-derived c

95 pproach to human melanoma cells treated with a panel of cancer therapeutics, we track dynamic changes

96 Using a panel of cardiac glycoside variants, we assessed the s

97 An analysis of a panel of CD200R-CD28 IFP constructs revealed that the

98 o measure differences in BER capacity across a panel of cell lines collected from healthy individuals

99 ated the consequences of inhibiting KDM1A in a panel of cell lines representing all acute myelogenous

100 In this study, we aimed to evaluate a panel of cell lines to identify a subset that would be

101 8 Mb chromosome 7 region surrounding CFTR in a panel of cell types.

102 Staphylococcus aureus expresses a panel of cell wall-anchored adhesins, including protei

103 Here, using a panel of cell- and compartment-specific IFN-gamma rece

104 steine-rich extracellular domains to produce a panel of chimeric molecules that held the target epito

105 rize HBeAg, we used phage display to produce a panel of chimeric rabbit/human monoclonal antibody fra

106 del of influenza A virus (IAV) infection and a panel of chromosome Y (ChrY) consomic strains on the C

107 A panel of clinical biomarkers accurately classified typ

108 reported here as MS-AFST, was assessed with a panel of clinical isolates that were selected to repre

109 A panel of clinician-geneticists rated the appropriatene

110 ifferent sensory characteristics reported by a panel of coffee tasters.

111 Using isogenic cells and a panel of colorectal and lung cell lines we demonstrate

112 Consider the problem of designing a panel of complex biomarkers to predict a patient's hea

113 Last, a panel of content experts selects the abstracts that ar

114 We assembled a panel of CRC organoids carrying either wild-type or mu

115 omplex multisynaptic circuit, we constructed a panel of Cre recombinase-activated pseudorabies viruse

116 kers, including C-reactive protein (CRP) and a panel of cytokines (interleukin-6 (IL-6) and tumor nec

117 tures in the livers, including AST, ALT, and a panel of cytokines and chemokines, were examined.

118 By screening a panel of deletion mutants of mouse cytomegalovirus (MC

119 Using a panel of diabetogenic CD4 T cell clones derived from t

120 untargeted metabolomics approach to identify a panel of diagnostically meaningful compounds that may

121 mycorrhizal inoculation was investigated in a panel of diverse maize lines.

122 iates virus replication, can be inhibited by a panel of drugs that are commercially available.

123 Here, we generated a panel of eight murine monoclonal antibodies (MAbs) uti

124 d severe malaria on levels of IE adhesion to a panel of endothelial receptors.

125 e-forming capabilities, as well as expressed a panel of epithelial stem cell-related genes, thus conf

126 ted proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines.

127 rection of CD4(+) and CD8(+) T cells against a panel of established blood cancers and primary, patien

128 ere confirmed by staining cell cultures with a panel of EV-specific antibodies.

129 ect and as broad-spectrum antivirals against a panel of EVs representative of all major species.

130 noise and performed well in comparison with a panel of existing methods on a controlled simulated da

131 A panel of expert hernia-surgeons was assembled.

132 tional Academy of Sciences recently convened a panel of experts to undertake a comprehensive study of

133 To develop the BEC, the AAP convened a panel of experts with knowledge of CBCT and substantia

134 gration of data from patient tumors revealed a panel of five microRNAs (miRNAs) (miR-124, miR-365, mi

135 Here, we analyse a panel of five murine anti-neuraminidase monoclonal ant

136 Using a panel of five mutant laboratory strains, we show the e

137 of the sensor was examined by blind testing a panel of food-contaminating pathogens (Listeria monocy

138 ll viability of over 50% when tested against a panel of four pancreatic cancer cell lines in vitro.

139 We evaluated the impact of a panel of FoxP3 mutants on its transcriptional activity

140 nces the aforementioned effector mechanisms, a panel of fusion proteins consisting of a CD20 or CD52

141 rticle biogenesis, we generated and analyzed a panel of Gag proteins with chimeric HIV-1/HTLV-1 CA do

142 ited superior analytical sensitivity against a panel of gametocyte-spiked whole blood, detecting 10 g

143 We identified a panel of genes consistently upregulated by tumor blood

144 l-b plasmocytes show increased expression of a panel of genes known to be dysregulated in human MM pa

145 Here we describe a panel of genetic screens to identify genes required fo

146 une sera showed antiviral activities against a panel of genetically distinct HCMV clinical isolates.

147 associated with GWAS loci in both humans and a panel of genetically diverse mice.

148 Furthermore, using a panel of genotypes from the Drosophila Synthetic Popul

149 glycoproteomics and the strategy to validate a panel of glycoproteins identified as potential biomark

150 converted into LacNAc and then elaborated by a panel of glycosyltransferases.

151 Compounds were tested against a panel of Gram-negative bacteria and counter-screened f

152 Evaluation of antibacterial activity against a panel of Gram-positive and Gram-negative bacteria reve

153 which improved antibacterial potency across a panel of Gram-positive organisms.

154 lutination inhibition (HAI) response against a panel of H1N1 viruses isolated over the past 100 years

155 antibodies with broader HAI activity against a panel of H3N2 viruses than wild-type H3 HA vaccines.

156 E], and chloral hydrate), to ethanol, and to a panel of halogenated methanes and alcohols.

157 ent triamino scaffold that is active against a panel of hard-to-kill epithelial cancer cell lines (in

158 ied allele-specific quantification assays to a panel of HD lymphoblastoid cell lines, each carrying t

159 ns of the enzyme inhibitory activity against a panel of HDAC isoforms revealed these compounds had st

160 s with an average titer of about 115 against a panel of heterologous Tier 2 isolates.

161 We generated a panel of high-affinity monobodies directed to each of

162 llected from the livers of mice treated with a panel of highly efficacious hepatotoxic or non-hepatot

163 In this study, we examined a panel of human anti-Env antibodies for their ability t

164 w by X-ray crystallography and by binding to a panel of human antibodies that these engineered dimers

165 rein synthesized were also evaluated against a panel of human cancer cells demonstrating a promising

166 cing on a range of CpG island targets across a panel of human cell lines and primary tissues.

167 We used basal transcriptomics data from a panel of human lymphoblastoid cell lines (LCL) to infe

168 therapeutic agents against ZIKV, we isolated a panel of human monoclonal antibodies from subjects tha

169 We conducted a reporter-based screen in a panel of human tumors to identify secreted factors tha

170 it improves yield in an inbred as well as in a panel of hybrids, at several locations and over multip

171 Importantly, a panel of IDU+/HCV+-associated CpGs discriminated HIV f

172 se element signalling pathways and activated a panel of IFN-regulated genes, antiviral mediators and

173 displayed dominant ADCP activity compared to a panel of IgG1 MAbs.

174 homeostasis, with upregulated expression of a panel of immune-regulatory genes, which was distinctly

175 S9 expression discriminated human Mregs from a panel of in vitro derived macrophages in other polaris

176 these sites, we tested for associations with a panel of inflammatory biomarkers measured in plasma ob

177 A panel of influenza A viruses expressing chimeric hemag

178 Using a panel of inhibitors against components of the TCR sign

179 By systematic screening using a panel of interferon-stimulated genes we identify two s

180 To do so, we established a panel of iPSCs from 58 well-studied Yoruba lymphoblast

181 ically representative epidemic M1 strain and a panel of isogenic mutant derivative strains, we evalua

182 o comprehensively assay genetic variation in a panel of known amyotrophic lateral sclerosis genes in

183 rt recognition of such a potential obstacle, a panel of leading experts in the field attempts here to

184 e probe the native or exposed features using a panel of lectins or glycan-binding reagents.

185 A panel of ligand-binding blocking and non-blocking anti

186 is positively correlated with expression of a panel of lipid-associated genes, indicating a role of

187 1/2 in combination with Bcl-XL inhibition on a panel of liver cancer cells.

188 This work identifies a panel of lncRNAs that appear to be prognostic in gliom

189 y correlated with the USP10 protein level in a panel of lung cancer cell lines.

190 associated with daunorubicin IC50 values in a panel of lymphoblastoid cell lines.

191 In our prior work, we identified a panel of macropinocytosing human monoclonal antibodies

192 f the infected lymphocytes to be targeted by a panel of major histocompatibility complex (MHC) class

193 lective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and

194 ovel inhibitors and their precursors against a panel of membrane-bound CA isoforms, including tumor-o

195 resting activity profiles when co-treated in a panel of metal(II) cations in MIC assays.

196 With the use of a panel of MHC-III recombinant inbred strains, we found

197 A panel of minigenes of varying splicing potential were

198 ions of 4,6-tethered glucosazide donors with a panel of model acceptors revealed the effect of accept

199 We have synthesized a panel of model unhooked nitrogen mustard ICLs to syste

200 Testing a panel of modulators of cAMP and cGMP signaling pathway

201 use medicinal chemistry concepts to assemble a panel of molecules to test how heteroaromatic ring sub

202 Using a panel of monoclonal antibodies (MAbs) that recognize k

203 ity were measured by antigenic analysis with a panel of monoclonal antibodies and by detecting change

204 arch for novel analgesics, we have generated a panel of monoclonal antibodies directed against human

205 fRH5 receptor basigin and were recognized by a panel of monoclonal antibodies.

206 Expression of DHRS9 within a panel of monocyte-derived macrophages was investigated

207 s-(+)-1d, showed remarkable selectivity over a panel of more than 15 receptors as well as good chemic

208 rescence in TUBO-derived tumorspheres and in a panel of mouse and human triple negative breast cancer

209 sion profiles of each of the Ras isoforms in a panel of mouse tissues derived from a full development

210 Screening of a panel of mouse tissues revealed that Clec2e transcript

211 Here, we utilized a panel of mutant HIV strains to demonstrate that in cel

212 ysis of the Cdc42 interface on ACK, creating a panel of mutant proteins with which we can now describ

213 We generated a panel of mutant rat strains in which specific modifica

214 ansporters, and from this strain, we created a panel of mutants where each expresses a single transpo

215 A panel of national experts in pediatric dermatology, pr

216 xhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK

217 Using a panel of Nef alleles isolated from diverse primate len

218 xamining the gene and protein expressions of a panel of neural/RGC markers.

219 In this study, with a panel of neutralizing antibodies from three healthy hu

220 We quantitatively validate this approach on a panel of nine distinct monoclonal antibodies targeting

221 To address this, a panel of nine monoclonal antibodies were generated aga

222 In contrast, a panel of normal cell types did not express MC2 mRNA, a

223 Using a panel of normal human fibroblasts, we characterized mo

224 TANCE This study describes the generation of a panel of novel anti-ebolavirus glycoprotein monoclonal

225 h morphogenesis of poxviruses and identifies a panel of novel inhibitors of poxvirus replication.

226 thylamino flavylium heterocycle to construct a panel of novel red-shifted polymethine dyes, with emis

227 atment with STAT3 and BCL6 inhibitors across a panel of NSCLC cell lines and in xenografted tumors si

228 pendent gene transcription, or activation of a panel of oncogenic kinases in malignant cells.

229 We show that MICU1 is overexpressed in a panel of ovarian cancer cell lines and that MICU1 over

230 oledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer cells.

231 cytokine) and IFN-gamma (Th1) in response to a panel of overlapping peptides spanning the above-liste

232 In this study, we utilize a panel of P. aeruginosa burn wound and cystic fibrosis

233 tor of IFN genes for type I IFN induction by a panel of pathogenic bacteria and DNA viruses.

234 ntal Therapeutics Program of NIH/NCI against a panel of pathogenic fungi including Candida species, A

235 the response kinetics to BRAF inhibition for a panel of patient-derived BRAF(V600) -mutant melanoma c

236 , through an analysis of TCR sequences using a panel of peptide and major histocompatibility complex

237 arkers for detecting malignant potential was a panel of peptides from mucin-5AC and mucin-2, which co

238 st cyclopropenones were further treated with a panel of phosphine probes, and reaction rates were mea

239 From a panel of phytoestrogen isoflavones, biochanin A (BCA)

240 severity of an epileptogenic insult and that a panel of plasma VD3 metabolites may be able to serve a

241 y allowed for a high-throughput screening of a panel of polymer carriers toward efficient cytosolic d

242 Using a panel of preterm transgenic mice, we show that epiderm

243 various IEM based on reliable measurement of a panel of primary or secondary biomarkers above an uppe

244 We identified a panel of prognostic proteins, confirmed with alternati

245 ciently responded toward CLL cells, released a panel of proinflammatory cytokines and lytic factors,

246 nities, we developed SNPDelScore, which uses a panel of proposed methods for quantifying deleterious

247 or tissues, and verified their mRNA level in a panel of prostate cancer cell lines.

248 By constructing a panel of protease mutants in strain K279a, we were abl

249 We screened a panel of proteases in the coagulation, fibrinolytic, a

250 We identify a panel of Ptchd1-interacting proteins that include post

251 a cells that reflect its selectivity against a panel of pure histone methyl transferases.

252 We define a panel of putative protein mdx biomarkers to evaluate u

253 In the present study, we develop a panel of rationally designed PPARdelta agonists.

254 indicates high affinity and selectivity over a panel of receptors including 5-HT2B subtype and hERG c

255 quinoline derivatives were evaluated against a panel of receptors/channels/transporters in radioligan

256 estigate the function of pUL33, we generated a panel of recombinant viruses with either deletions or

257 ation is reported on the temporal profile of a panel of renal biomarkers in sepsis in the context of

258 ity to sensitize TRAIL-mediated apoptosis in a panel of renal carcinoma cells.

259 A panel of retina specialists.

260 A panel of retinal specialists determined the ground tru

261 Previous studies have identified a panel of RNA transcripts of very low protein-coding po

262 lex, dMtr4 and dZcchc7, as antiviral against a panel of RNA viruses.

263 ative functional assay, we have now analyzed a panel of RRE mutants.

264 A panel of RT-PCR assays was used to detect noninfluenza

265 (4o), with IC50 values of 0.4-3.8 nM against a panel of seven cancer cell lines.

266 ated with differential cellular responses to a panel of signaling and epigenetic inhibitors.

267 o further elucidate its function, we created a panel of single-VH domain antibodies (VHHs) that recog

268 To determine utility of a panel of six fluorescent labeled antibodies as a diagn

269 The combined assessment of a panel of six serum TMs is a more accurate marker for L

270 In the current study, we screened a panel of small molecules focused on modulating differe

271 Here, we screened a panel of small molecules targeting epigenetic modulato

272 We have also identified a panel of ssUVR target genes that exhibited persistent

273 he loss of macroH2A1 increased expression of a panel of stemness-associated genes and drove hyperacti

274 e chitinases and from this strain, generated a panel of strains where each expresses a single chitina

275 adolescents' microbiota was characterized by a panel of streptococci, including S. mutans, S. sobrinu

276 ssed as a soluble protein and evaluated with a panel of substrates (both simple and complex mimetics

277 Accordingly, 1 reacts rapidly with a panel of substrates via C-H hydrogen atom transfer (HA

278 Analysis of a panel of subtype B transmitted/founder viruses showed

279 Wnt signaling-inhibitory antibody (HS20) and a panel of synthetic HS oligosaccharides with distinct l

280 To screen for TcdB-derived CPPs, a panel of synthetic peptides was tested for the ability

281 A panel of systemic inflammatory markers and soluble vas

282 le target epitopes, we tested the effects of a panel of tau antibodies on neuronal uptake and aggrega

283 ained low heteroplasmic point mutations, but a panel of ten individual iPSC lines from each tissue or

284 potent antiproliferative activities against a panel of tested tumor cell lines along with a better s

285 A panel of three proteins, namely EIF2B1, PRPS1L1 and MA

286 trophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and pro

287 sites and the expression of each gene across a panel of tissues.

288 We assessed a panel of TLR and STING agonists (a) for their ability

289 racterize (1) doxorubicin uptake dynamics in a panel of TNBC cell lines, and (2) cell population resp

290 erformed binding and functional studies with a panel of truncated ADAMTS13 variants.

291 By analyzing 96 different genes in a panel of tumor samples, we demonstrated that liver tum

292 We developed a panel of tunable expression platforms for the prominen

293 en proneural glioma mouse model, we assessed a panel of tyrosine kinase inhibitors with different sel

294 Here, we isolated and characterized a panel of vaccine-elicited cross-reactive neutralizing

295 odies, using well-characterized controls and a panel of validation methods.

296 parasite invasion into knockdown cells using a panel of wild-type P. falciparum laboratory strains an

297 ed as cardiovascular or noncardiovascular by a panel of WISE cardiologists masked to angiographic dat

298 of beta-catenin result in the expression of a panel of Wnt target genes.

299 plaque reduction neutralization test) using a panel of WT JE strains at baseline, then after the boo

300 t of a trapped monomer and trapped dimer and a panel of WT lysine/arginine to alanine mutants.